Drug Discovery and Preclinical Molecules by Therapy Area - Innovation Focuses on Stem Cell Therapies and Gene Therapies - GBI Research Reports

Drug Discovery and Preclinical Molecules by Therapy Area - Innovation Focuses on Stem Cell Therapies and Gene Therapies

Drug Discovery and Preclinical Molecules by Therapy Area - Innovation Focuses on Stem Cell Therapies and Gene Therapies - GBI Research Reports
Drug Discovery and Preclinical Molecules by Therapy Area - Innovation Focuses on Stem Cell Therapies and Gene Therapies
Published Feb 10, 2011
209 pages — Published Feb 10, 2011
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

GBI Researchs new report, Drug Discovery and Preclinical Molecules by Therapy Area - Innovation Focuses on Stem Cell Therapies and Gene Therapies, provides an in-depth analysis of the unmet needs, drivers and barriers that affect the global Central Nervous System Disorders (CNS), Metabolic Disorders, Immunologic Disorders, Infection, Cardiovascular Disease and Oncology therapeutic markets. The report analyzes the early stage drug development that includes drugs under development in the discovery and preclinical stages of development for the above mentioned indications in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales value and the annual cost of therapy are forecast until 2017 for the key geographies in the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the Mergers and Acquisitions (M&A) and licensing agreements that shape the global market.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Researchs team of industry experts.
GBI Research finds that early stage drug development includes drugs under development in the discovery and preclinical stages of development. These studies are conducted in order to assess the safety and efficacy of the drug. This stage of development plays a key role in drug development as it determines potential molecules to be further processed for development by different companies. Increased strategies like RAS (Risk Assessment Strategies) issued by the US FDA (Food and Drug Administration) are persuading companies to implement safety scrutiny measures at early stages of development.

The majority of the molecules in the early stages of development are being developed for cancer indications. Molecules under development for breast cancer account for 23% of the total early stage development molecules under development for cancer. This is followed by prostate cancer, accounting for 20%, followed by colon cancer (15%).

Other than Oncology, other therapeutic areas with high activity in Research and Development (R&D) in early development phases include Central Nervous System (CNS) disorders, immunological disorders, and metabolic disorders. CNS disorders accounted for 14% of early stage drugs under development, followed by immunological disorders (13%) and metabolic disorders (10%). Compared to other therapeutic areas, there is less R&D activity in the metabolic disorders (9%) and infectious disease (9%) segments.

Scope

- Coverage of pipeline molecules in various discovery and pre-clinical phases of drug development along with pipeline analysis of the leading therapeutic segments, including Oncology, CNS disorders, immunological disorders, infection, metabolic disorders and cardiovascular disorders
- Analysis of the above mentioned disorders market in the leading geographies of the world, which are the US, the UK, Germany, France, Italy, Spain and Japan
- Key drivers and barriers that have a significant impact on the market
- Competitive benchmarking of leading companies. The key companies studied in this report are Hanall Pharmaceutical Co. Ltd, Patrys Limited, F. Hoffmann-La Roche Ltd, Mirna Therapeutics, Inc. and Aphios Corporation
- Key M&A activities and licensing agreements that have taken place between 2005 and 2010 in the global Oncology, CNS disorders, immunological disorders, infection, metabolic disorders and cardiovascular disorders markets

Reasons to buy

- Align your product portfolio to the markets with high growth potential
- Develop market-entry and market expansion strategies by identifying the lead

  
Source:
Document ID
GBIHC076MR
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents46
  List of Tables62
  List of Figures82
Drug Discovery and Preclinical Molecules by Therapy Area Introduction102
  GBI Research Report Guidance111
Drug Discovery and Preclinical Molecules by Therapy Area - Overview126
  Drug Discovery and Development121
    Drug Development-Stages131
      Early Stage Drug Discovery131
      Phase I141
      Phase II141
      Phase III141
      Registration141
      Phase IV151
  Early Stage Drug Discovery Studies- An overview151
  Early Stage Drug Discovery Design and Planning161
    Early Stage Drug Discovery Strategic Planning161
    Key Considerations During Early Stage Drug Discovery162
Drug Discovery and Preclinical Molecules by Therapy Area - Technology Landscape189
  Current System181
    Overview181
    Key Technologies181
    In-vitro ADMET Screening Models191
    In vivo ADMET Screening Models201
    In silico ADMET Screening models211
  Trends in Technology Models221
    Recent Technology Developments225
Drug Discovery and Preclinical Molecules by Therapy Area - Drug Discovery and Development A Challenge to Pharmaceutical Companies271
  Drug Discovery &Development Process271
    Drug Discovery Process271
Drug Discovery and Preclinical Molecules in Therapeutic Segments28158
  Central Nervous System Disorders311
    Alzheimer s disease311
      Drivers and Barriers for the Alzheimer s disease Therapeutics Market311
      Early Stage Research and Development Pipeline Alzheimer s disease323
      R&D Pipeline by Phase in Alzheimer s disease351
      R&D Pipeline by Mechanism of Action in Alzheimer s disease361
    Parkinson s disease371
      Drivers and Barriers for the Parkinson s disease Therapeutics371
      Early Stage Research and Development Pipeline Parkinson s disease382
      R&D Pipeline by Phase in Parkinson s disease401
      R&D Pipeline by Mechanism of Action in Parkinson s disease411
    Multiple Sclerosis421
      Drivers and Barriers for the Multiple Sclerosis Therapeutics Market422
      Early Stage Research and Development Pipeline Multiple Sclerosis441
      R&D Pipeline by Phase in Multiple Sclerosis451
      R&D Pipeline by Mechanism of Action in Multiple Sclerosis461
    Schizophrenia471
      Drivers and Barriers for the Schizophrenia Therapeutics Market481
      Early Stage Research and Development Pipeline Schizophrenia491
      R&D Pipeline by Phase in Schizophrenia501
      R&D Pipeline by Mechanism of Action in Schizophrenia511
  Metabolic Disorders521
    Diabetes521
      Drivers and Barriers for the Diabetes Therapeutics Market522
      Early Stage Research and Development Pipeline Diabetes543
      R&D Pipeline by Phase in Diabetes571
      R&D Pipeline by Mechanism of Action in Diabetes581
    Obesity591
      Drivers and Barriers for the Obesity Therapeutics Market592
      Early Stage Research and Development Pipeline Obesity612
      R&D Pipeline by Phase in Obesity631
      R&D Pipeline by Mechanism of Action in ObesityTherapeutics641
  Immunological Disorders651
    Rheumatoid Arthritis651
      Drivers and Barriers for the RA Therapeutics Market652
      Early Stage Research and Development Pipeline Rheumatoid ArthritisTherapeutics673
      R&D Pipeline by Phase in RA Therapeutics701
      R&D Pipeline by Mechanism of Action in Rheumatoid ArthritisTherapeutics711
    Crohn s Disease721
      Drivers and Barriers for the Crohn s Disease Therapeutics Market722
      Early Stage Research and Development Pipeline Crohn s Disease741
      R&D Pipeline by Phase in Crohn s Disease751
      R&D Pipeline by Mechanism of Action in Crohn s disease761
    Systemic Lupus Erythematosus (SLE)771
      Drivers and Barriers for the SLE Therapeutics Market772
      Early Stage Research and Development Pipeline Systemic Lupus Erythematosus Therapeutics791
      R&D Pipeline by Phase in Systemic Lupus Erythematosus Therapeutics801
      R&D Pipeline by Mechanism of Action in Systemic Lupus Erythematosus Therapeutics811
    Allergy821
      Drivers and Barriers for the Allergy Therapeutics Market822
      Early Stage Research and Development Pipeline Allergy Therapeutics841
      R&D Pipeline by Phase in Allergy Therapeutics851
      R&D Pipeline by Mechanism of Action in Allergy Therapeutics861
  Infections871
    HIV/AIDS871
      Drivers and Barriers for the HIV/AIDS Therapeutics Market875
      Early Stage Research and Development Pipeline HIV/AIDS Therapeutics922
      R&D Pipeline by Phase in HIV/AIDS Therapeutics941
      R&D Pipeline by Mechanism of Action in HIV/AIDS Therapeutics951
    Hepatitis A, B, C961
      Drivers and Barriers for the Hepatitis Therapeutics Market972
      Early Stage Research and Development Pipeline- Hepatitis A, B &C Therapeutics993
      R&D Pipeline by Phase in Hepatitis A, B &C Therapeutics1021
      R&D Pipeline by Mechanism of Action in Hepatitis A, B &C Therapeutics1031
  Cardiovascular Diseases1041
    Hypertension1041
      Drivers and Barriers for the Hypertension Therapeutics Market1051
      Early Stage Research and Development Pipeline Hypertension Therapeutics1061
      R&D Pipeline by Phase in Hypertension Therapeutics1071
      R&D Pipeline by Mechanism of Action in HypertensionTherapeutics1081
    Dyslipidemia1091
      Drivers and Barriers for the Dyslipidemia Therapeutics Market1092
      Early Stage Research and Development Pipeline Dyslipidemia Therapeutics1111
      R&D Pipeline by Phase in Dyslipidemia Therapeutics1121
      R&D Pipeline by Mechanism of Action in Dyslipidemia Therapeutics1131
    Pulmonary Arterial Hypertension (PAH)1142
      Drivers and Barriers for the PAH Therapeutics Market1161
      Early Stage Research and Development Pipeline- PAH Therapeutics1171
      R&D Pipeline by Phase in PAH Therapeutics1171
      R&D Pipeline by Mechanism of Action in PAH Therapeutics1181
    Myocardial Infarction1191
      Drivers and Barriers for the Myocardial infarction Therapeutics Market1201
      Early Stage Research and Development Pipeline Myocardial Infarction Therapeutics1211
      R&D Pipeline by Phase in Myocardial Infarction Therapeutics1221
      R&D Pipeline by Mechanism of Action in Myocardial Infarction Therapeutics1231
  Oncology1241
    Bladder Cancer1241
      Drivers and Barriers for the Bladder Cancer Therapeutics Market1251
      Early Stage Research and Development Pipeline Bladder Cancer Therapeutics1261
      R&D Pipeline by Phase in Bladder Cancer Therapeutics1271
      R&D Pipeline by Mechanism of Action in Bladder Cancer Therapeutics1272
    Lung Cancer1292
      Drivers and Barriers for the Lung Cancer Therapeutics Market1312
      Early Stage Research and Development Pipeline Lung Cancer Therapeutics1332
      R&D Pipeline by Phase in Lung Cancer Therapeutics1351
      R&D Pipeline by Mechanism of Action in Lung Cancer Therapeutics1361
    Non-Small Cell Lung Cancer (NSLC)1372
      Drivers and Barriers for the NSLC Therapeutics Market1391
      Early Stage Research and Development Pipeline NSLC Therapeutics1401
      R&D Pipeline by Phase in NSLC Therapeutics1411
      R&D Pipeline by Mechanism of Action in NSLC Therapeutics1421
    Breast Cancer1434
      Drivers and Barriers for the Breast Cancer Therapeutics Market1471
      Early Stage Research and Development Pipeline Breast Cancer1484
      R&D Pipeline by Phase in Breast Cancer Therapeutics1521
      R&D Pipeline by Mechanism of Action in Breast Cancer Therapeutics1531
    Colon Cancer1543
      Drivers and Barriers for the Colon Cancer Therapeutics Market1571
      Early Stage Research and Development Pipeline Colon Cancer Therapeutics1583
      R&D Pipeline by Phase in Colon Cancer Therapeutics1611
      R&D Pipeline by Mechanism of Action in Colon Cancer Therapeutics1621
    Melanoma1632
      Drivers and Barriers for the Melanoma Therapeutics Market1651
      Early Stage Research and Development Pipeline Melanoma Therapeutics1662
      R&D Pipeline by Phase in Melanoma Therapeutics1681
      R&D Pipeline by Mechanism of Action in Melanoma Therapeutics1691
    Ovarian Cancer1701
      Drivers and Barriers for the Ovarian Cancer Therapeutics Market1711
      Early Stage Research and Development Pipeline Ovarian Cancer Therapeutics1722
      R&D Pipeline by Phase in Ovarian Cancer Therapeutics1741
      R&D Pipeline by Mechanism of Action in Ovarian Cancer Therapeutics1752
    Prostate Cancer1771
      Drivers and Barriers for the Prostate Cancer Therapeutics Market1781
      Early Stage Research and Development Pipeline Prostate Cancer Therapeutics1794
      R&D Pipeline by Phase in Prostate Cancer Therapeutics1831
      R&D Pipeline by Mechanism of Action in Prostate Cancer Therapeutics1842
Drug Discovery and Preclinical Molecules by Therapy Area Top Five Pharmaceutical Players in Early Stage Drug Discovery1867
  Introduction1861
  Hanall Pharmaceutical1871
    Company Overview1871
    Pipeline1871
  Patrys Limited1881
    Company Overview1881
    Pipeline1891
  F. Hoffmann-La Roche Ltd.1891
    Company Overview1891
    Pipeline1901
  Mirna Therapeutics1901
    Company Overview1901
    Pipeline1911
  Aphios Corporation1911
    Company Overview1911
    Pipeline1921
Drug Discovery and Preclinical Molecules by Therapy Area Strategic Consolidations1939
  R&D Licensing Agreements1931
    Deals by Indication1931
    Deals by Geography1941
    Deal Summaries by Therapeutic Class1951
      Metabolic Disorders1951
      Immunolgical Disorders1962
      Cardiovascular Disorders1981
      Infection1991
      Oncology2001
      Central Nervous System Disorders2011
Drug Discovery and Preclinical Molecules by Therapy Area Appendix2028
  Market Definitions2021
  Abbreviations2025
  Research Methodology2072
    Coverage2071
    Secondary Research2071
    Primary Research2081
    Expert Panel Validation2081
  Contact Us2081
  Disclaimer2081
  Sources2091

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "Drug Discovery and Preclinical Molecules by Therapy Area - Innovation Focuses on Stem Cell Therapies and Gene Therapies" Feb 10, 2011. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Drug-Discovery-and-Preclinical-Molecules-by-Therapy-Area-Innovation-Focuses-on-Stem-Cell-Therapies-and-Gene-Therapies-2115-163>
  
APA:
GBI Research Reports. (2011). Drug Discovery and Preclinical Molecules by Therapy Area - Innovation Focuses on Stem Cell Therapies and Gene Therapies Feb 10, 2011. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Drug-Discovery-and-Preclinical-Molecules-by-Therapy-Area-Innovation-Focuses-on-Stem-Cell-Therapies-and-Gene-Therapies-2115-163>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.